SCM
CLDX icon

Sterling Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Sterling Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.8K Sell
2,170
-1,639
-43% -$44.7K ﹤0.01% 1517
2025
Q4 		$103K Sell
3,809
-726
-16% -$19.1K ﹤0.01% 1517
2025
Q3 		$117K Buy
4,535
+2,767
+157% +$64.1K ﹤0.01% 1479
2025
Q2 		$36K Buy
1,768
+1,509
+583% +$29.4K ﹤0.01% 1593
2025
Q1 		$4.7K Sell
259
-175
-40% -$3.91K ﹤0.01% 2193
2024
Q4 		$11K Buy
434
+336
+343% +$9.13K ﹤0.01% 2119
2024
Q3 		$3.33K Buy
+98
New +$3.73K ﹤0.01% 1939

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return